e-ISSN: Pending
Negative / Null Result ReportOpen accessMedicine· cited by 70

A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease

Ted Wun; Denis Soulières; Andrew L. Frelinger; Lakshmanan Krishnamurti; Enrico M. Novelli; Abdullah Kutlar; Kenneth I. Ataga; Charles Knupp · 2013 · Journal of Hematology & Oncology

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

BACKGROUND: Platelet activation has been implicated in the pathogenesis of sickle cell disease (SCD) suggesting antiplatelet agents may be therapeutic. To evaluate the safety of prasugrel, a thienopyridine antiplatelet agent, in adult patients with SCD, we conducted a double-blind, randomized, placebo-controlled study. METHODS: The primary endpoint, safety, was measured by hemorrhagic events requiring medical intervention. Patients were randomized to prasugrel 5 mg daily (n = 41) or placebo (n = 21) for 30 days. Platelet function by VerifyNow® P2Y12 and vasodilator-stimulated phosphoprotein as

Abstract by Ted Wun; Denis Soulières; Andrew L. Frelinger; Lakshmanan Krishnamurti; Enrico M. Novelli; Abdullah Kutlar; Kenneth I. Ataga; Charles Knupp, Journal of Hematology & Oncology (2013) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1186/1756-8722-6-17